Search

Displaying results 5821 - 5830 of 6279 in total
  1. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14405
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  2. Drug

    Influenza B virus B/Brisbane/9/2014 hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14406
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  3. Drug

    Influenza A virus A/South Australia/55/2014 IVR-175 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14408
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  4. Drug

    Influenza A virus A/Victoria/361/2011 IVR-165 (H3N2) hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14411
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  5. Drug

    Influenza B virus B/Hubei-Wujiagang/158/2009 BX-39 hemagglutinin antigen (propiolactone inactivated)

    go.drugbank.com/drugs/DB14412
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  6. Drug

    Influenza A virus A/Hong Kong/4801/2014 X-263B (H3N2) hemagglutinin antigen (formaldehyde inactivated)

    go.drugbank.com/drugs/DB14413
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  7. Drug

    Influenza A virus A/California/7/2009 X-179A (H1N1) hemagglutinin antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14414
    ApprovedWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  8. Drug

    Influenza A virus A/Switzerland/9715293/2013 NIB-88 (H3N2) hemagglutinin antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14415
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  9. Drug

    Influenza B virus B/Phuket/3073/2013 hemagglutinin antigen (UV, formaldehyde inactivated)

    go.drugbank.com/drugs/DB14416
    Approved

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it

  10. Drug

    Influenza A virus A/Hong Kong/4801/2014 (H3N2) recombinant hemagglutinin antigen

    go.drugbank.com/drugs/DB14417
    ApprovedInvestigationalWithdrawn

    This defence includes the production of humoral immunity through the development of antibodies (through memory B cells) and of cell-mediated immunity through the production of T-lymphocytes. … re-exposure to infectious influenza virus, the immune system is prepared to identify and destroy the virus as there are circulating antibodies that recognize that particular component of the virus that it